TVRD
Tvardi Therapeutics, Inc.
$2.02
+0.07 (+3.59%)
At close · Jul 2
Market Cap
$18.95M
Shares
9,381,344
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.02
Open$1.93
Day$1.91–2.08
52W$1.50–43.65
Avg vol 30d278K
Short int398K · 4.2% float · 6.9d
Short vol32%
Last earningsMay 8, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−72% below
−
Price vs 50-day avg
−35% below
◦
RSI (14)
35 · neutral
−
MACD trend
negative
−
52-week position
1% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $3 › 200d $7 — 200d above 50d
+
Institutional flow
+2% holders QoQ · +15 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
4.24% of float · ▼ -8.7% MoM · 6.9 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
66 holders — near 1-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+959% Y/Y
+
EPS growth
+71% Y/Y
−
Free cash flow
$-24.5M
+
Balance sheet
net cash $20.7M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−72% below
Bearish
Price vs 50-day avg
−35% below
Bearish
RSI (14)
35 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
1% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.24% of float · ▼ -8.7% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 1%
52-wk high $44
vs 200-day avg -72%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TVRD
this stock
Tvardi Therapeutics, Inc.
|
$18.95M | -53.0% | +959.3% | — | 4.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TVRD | -14.4% | -31.5% | -52.3% | +6.3% | -53.0% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -15.8% | -30.3% | -60.3% | +6.6% | -62.2% |